AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase IB, open-label, multi-center study titled MAGELLAN to assess the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line treatment of Stage IV Non-Small Cell Lung Cancer (NSCLC). This study aims to explore new treatment combinations to improve outcomes for patients with this aggressive cancer type.
Intervention/Treatment: The study is testing several interventions, including durvalumab, a known immunotherapy drug, in combination with other novel agents like danvatirsen, oleclumab, MEDI5752, and AZD2936. These combinations are designed to enhance the immune response against cancer cells.
Study Design: The study employs a randomized, parallel intervention model with no masking, meaning all participants and researchers know which treatment is being administered. The primary purpose is treatment-focused, aiming to identify effective first-line therapies for NSCLC.
Study Timeline: The study began on December 27, 2018, and is currently active but not recruiting new participants. The last update was submitted on July 21, 2025, indicating ongoing data collection and analysis.
Market Implications: This study’s progress could significantly impact AstraZeneca’s stock performance, as successful results may enhance its oncology portfolio and competitive position. Investors should monitor updates closely, as positive outcomes could boost investor confidence and influence market dynamics in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.